Atlanthera

ATLANTHERA is a drug discovery company focused on bone diseases and has developed a unique bone-targeted drug delivery technology. Atlanthera has made its proof of concept of bone targeting with its lead candidate in oncology, the new 12b80 molecule, which is now ready for clinical development. In parallel, our company is extending its therapeutic strategy to the osteoarticular targeting of anti-rheumatoid drugs (anti-inflammatory, antalgic and anti-chondrodegradation strategies) as well as anti-microbial drugs. Our objectives during BIO convention 2018: Licensing out and co-development collaborations.